This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014
CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months. If treatment is to be extended beyond six months, the following condition must be met.
Condition: A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months.
Subject indexing assigned by CRD
Anticoagulants; Humans; Morpholines; Pulmonary Embolism; Thiophenes
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published